Appili Therapeutics Inc. Stock Price

TSX:APLI Community·CA$3.0m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

Create a narrative

APLI Share Price Performance

CA$0.025

-0.01 (-28.57%)

CA$0.025

-0.01 (-28.57%)

CA$0.025

Mon, 10 Nov 25

Share PriceCA$0.025

APLI Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Slight risk and slightly overvalued.

4 Risks

2 Rewards

View Full Analysis

Appili Therapeutics Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -0.019
: 100.00%
: -2,279.26%
: -84.4%

View Full Analysis

About APLI

Founded: 2015
Employees: 7
CEO: Donald Cilla
WebsiteView website: appilitherapeutics.com

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.